SML0150

Tolcapone

≥98% (HPLC)

• 동의어(들): 3,4-Dihydroxy-4′-methyl-5-nitrobenzophenone, Ro 40-7592
• 실험식(Hill 표기법): C₁₄H₁₁NO₅
• CAS Number: 134308-13-7
• Molecular Weight: 273.24
• MDL number: MFCD00866569
• UNSPSC 코드: 12352200
• PubChem Substance ID: 329825198
• NACRES: NA.77

속성

• Quality Level: 100
• 분석: ≥98% (HPLC)
• 양식: powder
• 저장 조건: desiccated
• 색상: yellow
• solubility: DMSO: ≥15 mg/mL
• 주관자: Roche
• 저장 온도: 2-8°C
• SMILES string: Cc1ccc(cc1)C(=O)c2cc(O)c(O)c(c2)[N+]([O-])=O
• InChI: 1S/C14H11NO5/c1-8-2-4-9(5-3-8)13(17)10-6-11(15(19)20)14(18)12(16)7-10/h2-7,16,18H,1H3
• InChI key: MIQPIUSUKVNLNT-UHFFFAOYSA-N
• 유전자 정보: human ... COMT(1312)

설명

애플리케이션

Tolcapone may be used in COMT-mediated cell signaling studies.
Tolcapone has been used in methyltransferase assay in human embryonic kidney 293 cells.

생화학적/생리학적 작용

Inhibition of catechol-O-methyltransferase by tolcapone increases the half-life and bioavailabilty of levodopa. It therefore is an effective adjunctive therapy in patients with Parkinson′s disease with motor response fluctuations.

Orally active catechol-O-methyltransferase (COMT) inhibitor: inhibits both central and peripheral COMT.

Tolcapone is an orally active catechol-O-methyltransferase (COMT) inhibitor. It inhibits both central and peripheral COMT. Tolcapone crosses the blood-brain barrier, and has been used for L-DOPA adjunct therapy in the treatment of Parkinson′s Disease.

특징 및 장점

This compound was developed by Roche. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

안전성 정보

• 픽토그램: GHS09
• 신호어: Warning
• 유해 및 위험 성명서: H400
• 예방조치 성명서: P273 - P391 - P501
• Hazard Classifications: Aquatic Acute 1
• Storage Class Code: 11 - Combustible Solids
• WGK: WGK 3
• Flash Point (°F): Not applicable
• Flash Point (°C): Not applicable